Drug intelligence / Profile preview

GA-68-D0103

Development stage: Preclinical
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
Administration: Intravenous

Overview

GA-68-D0103 is a Gallium-68 (⁶⁸Ga) labeled radiopharmaceutical designed for Positron Emission Tomography (PET)/Computed Tomography (CT) imaging. It targets the αvβ6-integrin, a transmembrane receptor overexpressed in various carcinomas, including esophageal and pancreatic cancer. The drug utilizes tris(hydroxypyridinone) (THP) chelators conjugated to an αvβ6 integrin-selective peptide for stable gallium chelation and high-affinity binding. It is being investigated for its potential as a theranostic agent, combining diagnostic imaging with potential therapeutic applications.

Targets

αVβ6 (Integrin αVβ6)

Beyond the preview

Go deeper on GA-68-D0103.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GA-68-D0103.

Explore the full profile